Pramipexole transdermal delivery system and uses thereof

1. A transdermal patch for administration comprising:

(i) a drug-containing layer;

(ii) a backing layer; and

(iii) a protective layer,

wherein the drug-containing layer comprises:

(a) pramipexole or a pharmaceutically acceptable salt thereof,

(b) a combination of at least two permeation enhancers, wherein the permeation enhancers are selected from the group consisting of aliphatic alcohols, fatty acids having a chain of 8 to 20 carbons, fatty acid esters, alcohol amines, polyhydric alcohol alkyl ethers, polyoxyethylene alkyl ethers, glycerides, middle-chain fatty acid esters of polyhydric alcohols having a chain of 8-20 carbon atoms, alkyl esters having a chain of 1-6 carbon atoms, acylated amino acids, pyrrolidone, pyrrolidone derivatives, ethoxylated fatty alcohols, pharmaceutically acceptable surfactants and combinations thereof,

(c) a carboxyl functional group containing acrylic-based polymer comprising an acrylate copolymer of 2-ethylhexyl acrylate, vinyl acetate, butyl acrylate, acrylic acid and a crosslinker consisting of aluminum tris(acetyl acetonate) or an aluminium metal chelate, and

(d) a hydroxyl functional group containing acrylic-based polymer comprising an acrylate copolymer of 2-ethylhexyl acrylate, methyl acrylate and 2-hydroxyethyl acrylate or an acrylate copolymer of 2-ethylhexyl acrylate, vinyl acetate and 2-hydroxyethylacrylate;

wherein the carboxyl group-containing acrylic-based polymer and the hydroxyl group-containing acrylic-based polymer are in a ratio of from about 2:1 to about 1:2 by weight, wherein the transdermal patch provides flux rate of between about 6.3 μg/cm 2 hr and about 10 μg/cm 2 hr for up to about 40 hours, wherein lag time for the transdermal patch is about 8 hours or less, and wherein at least one permeation enhancer has pramipexole solubility of between about 50 mg/mL to about 122 mg/mL.

2. The transdermal patch of claim 1 , wherein the pramipexole or its pharmaceutically acceptable salt thereof is selected from pramipexole free-base, pramipexole dihydrochloride or dexpramipexole.

3. The transdermal patch of claim 1 , wherein the pramipexole or its pharmaceutically acceptable salt thereof is in an amount from about 2% to about 15% by weight of the drug-containing layer.

4. The transdermal patch of claim 1 , wherein an impurity level within pramipexole is about 1.0% or less by weight after up to about 2 weeks of storage, at a temperature up to about 60° C., and up to about 75% relative humidity.

5. The transdermal patch of claim 1 , wherein at least one of the permeation enhancers is selected from diethylene glycol monoethyl ether, methyl laurate, polyoxyethylene(4)lauryl ether, and/or propylene glycol.

6. The transdermal patch of claim 1 , wherein each acrylic-based polymer has pramipexole solubility between about 5% to about 10%.

7. The transdermal patch of claim 1 , wherein the transdermal patch provides a flux rate of between about 9.3 μg/cm 2 hr and about 10 μg/cm2 hr.

8. A method for treating Parkinson's disease, restless leg syndrome, migraine headaches or ALS comprising the step of administering the transdermal patch of claim 1 to a human subject in need thereof, wherein the transdermal patch comprises a therapeutically effective amount of the pramipexole or its pharmaceutically acceptable salt thereof.

9. The method of claim 8 , wherein the total delivered amount of pramipexole is from about 0.2 mg to about 10 mg daily.